The caspase-6 paradox: pro-tumorigenic functions but anti-tumor immunogenicity associated with potential immunoediting in colorectal cancer

While immune checkpoint inhibitors (ICIs) benefit patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC), most with microsatellite stable (MSS) disease are unresponsive. Caspase-6 (CASP6) is implicated in apoptosis and other processes, but its role as a biomarker in colorectal cancer (CRC) and the tumor immune microenvironment (TIME) remains unclear and contradictory. We combined bioinformatics and in vitro validation. CASP6’s clinical significance was analyzed using TCGA/HPA data. The effects of CASP6 knockdown via siRNA were assessed in HCT116 and Caco2 cells (proliferation, migration, apoptosis). Underlying mechanisms regarding the TIME and immunotherapy response were explored via GSEA, immune deconvolution (CIBERSORT, ESTIMATE), and immunophenoscore (IPS) analysis. CASP6 was downregulated in CRC tissues, and low mRNA expression correlated with poorer overall and progression-free survival. To dissect this clinical observation, we performed in vitro functional assays. Paradoxically, CASP6 knockdown suppressed cancer cell proliferation and migration while inducing apoptosis in vitro, suggesting a pro-tumorigenic role at the cellular level. However, this cell-intrinsic oncogenic effect contrasts with its role in the tumor microenvironment. Bioinformatics revealed that tumors with low CASP6 mRNA levels exhibited an immunosuppressive TIME, characterized by increased regulatory T-cell infiltration and elevated expression of immune checkpoints (PD-L1, CTLA-4). This suggests that the reduced CASP6 expression, while inhibiting cell-autonomous malignancy, may facilitate immune escape. Consequently, these tumors also had a higher IPS, predicting a better potential response to anti-PD-1/CTLA-4 therapy. This study reveals a dual role for CASP6: it promotes tumor cell malignancy cell-autonomously, yet its expression may enhance immunogenicity. Downregulation of CASP6 may represent an immune escape mechanism potentially driven by immunoediting, explaining its association with poor prognosis but also a more favorable immunotherapy context. Thus, CASP6 mRNA expression is a promising biomarker for stratifying CRC patients.

Authors

Institutions

Publication Details

Journal
Cancer Cell International
Published
2026-11-20
DOI
https://doi.org/10.1186/s12935-026-04511-z
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The caspase-6 paradox: pro-tumorigenic functions but anti-tumor immunogenicity associated with potential immunoediting in colorectal cancer

Yanhua Lyu, Liu Yingshan, Chenglong He, Jianjun Xiao et al.
3 links
Cancer Cell International
Cancer Immunotherapy and Biomarkers
article

The caspase-6 paradox: pro-tumorigenic functions but anti-tumor immunogenicity associated with potential immunoediting in colorectal cancer

Yanhua Lyu, Liu Yingshan, Chenglong He, Jianjun Xiao, Yuehua Huang, Wenjing Dong
article en

Abstract

While immune checkpoint inhibitors (ICIs) benefit patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC), most with microsatellite stable (MSS) disease are unresponsive. Caspase-6 (CASP6) is implicated in apoptosis and other processes, but its role as a biomarker in colorectal cancer (CRC) and the tumor immune microenvironment (TIME) remains unclear and contradictory. We combined bioinformatics and in vitro validation. CASP6’s clinical significance was analyzed using TCGA/HPA data. The effects of CASP6 knockdown via siRNA were assessed in HCT116 and Caco2 cells (proliferation, migration, apoptosis). Underlying mechanisms regarding the TIME and immunotherapy response were explored via GSEA, immune deconvolution (CIBERSORT, ESTIMATE), and immunophenoscore (IPS) analysis. CASP6 was downregulated in CRC tissues, and low mRNA expression correlated with poorer overall and progression-free survival. To dissect this clinical observation, we performed in vitro functional assays. Paradoxically, CASP6 knockdown suppressed cancer cell proliferation and migration while inducing apoptosis in vitro, suggesting a pro-tumorigenic role at the cellular level. However, this cell-intrinsic oncogenic effect contrasts with its role in the tumor microenvironment. Bioinformatics revealed that tumors with low CASP6 mRNA levels exhibited an immunosuppressive TIME, characterized by increased regulatory T-cell infiltration and elevated expression of immune checkpoints (PD-L1, CTLA-4). This suggests that the reduced CASP6 expression, while inhibiting cell-autonomous malignancy, may facilitate immune escape. Consequently, these tumors also had a higher IPS, predicting a better potential response to anti-PD-1/CTLA-4 therapy. This study reveals a dual role for CASP6: it promotes tumor cell malignancy cell-autonomously, yet its expression may enhance immunogenicity. Downregulation of CASP6 may represent an immune escape mechanism potentially driven by immunoediting, explaining its association with poor prognosis but also a more favorable immunotherapy context. Thus, CASP6 mRNA expression is a promising biomarker for stratifying CRC patients.

Cancer Cell International
Zhongshan People's Hospital (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon